retatrutide ly3437943 phase 2 trial obesity nejm 2023 triple agonist for diabetes type hormone receptor metabolic dysfunction-associated steatotic liver disease: a Retatrutide (LY3437943): Mechanism of Action

Carnitine supplements, known for their role in energy metabolism, fat oxidation, and cardiovascular support, fit well into this preventive approach

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

Commercial demand for these APIs can reach tens or even hundreds of kilograms annually, and in some cases may approach metric-ton production levels

For a detailed look at what to expect and potential considerations, read our guide on glutathione side effects and what to know before you start

A CL Member asked if, when taking an herbal supplement, liquids are better than powders